|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Baggstrom MQ, Stinchcombe TE, Fried DB,
Poole C, Hensing TA and Socinski MA: Third-generation chemotherapy
agents in the treatment of advanced non-small cell lung cancer: A
meta-analysis. J Thorac Oncol. 2:845–853. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Seto T, Kiura K, Nishio M, Nakagawa K,
Maemondo M, Inoue A, Hida T, Yamamoto N, Yoshioka H, Harada M, et
al: CH5424802 (RO5424802) for patients with ALK-rearranged advanced
non-small-cell lung cancer (AF-001JP study): A single-arm,
open-label, phase 1–2 study. Lancet Oncol. 14:590–598. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mok TS, Wu YL, Thongprasert S, Yang CH,
Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et
al: Gefitinib or carboplatin-paclitaxel in pulmonary
adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa
K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, et al:
PROFILE 1014 Investigators: First-line crizotinib versus
chemotherapy in ALK-positive lung cancer. N Engl J Med.
371:2167–2177. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ,
Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al:
Safety and activity of anti-PD-L1 antibody in patients with
advanced cancer. N Engl J Med. 366:2455–2465. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Brahmer J, Reckamp KL, Baas P, Crinò L,
Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE,
Holgado E, et al: Nivolumab versus Docetaxel in advanced
squamous-cell non-small-cell lung cancer. N Engl J Med.
373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pardoll DM: The blockade of immune
checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, et al: Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med.
366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dong H, Strome SE, Salomao DR, Tamura H,
Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al:
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential
mechanism of immune evasion. Nat Med. 8:793–800. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Igarashi T, Teramoto K, Ishida M, Hanaoka
J and Daigo Y: Scoring of PD-L1 expression intensity on pulmonary
adenocarcinomas and the correlations with clinicopathological
factors. ESMO Open. 1:e0000832016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Freeman GJ, Long AJ, Iwai Y, Bourque K,
Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne
MC, et al: Engagement of the PD-1 immunoinhibitory receptor by a
novel B7 family member leads to negative regulation of lymphocyte
activation. J Exp Med. 192:1027–1034. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Eppihimer MJ, Gunn J, Freeman GJ,
Greenfield EA, Chernova T, Erickson J and Leonard JP: Expression
and regulation of the PD-L1 immunoinhibitory molecule on
microvascular endothelial cells. Microcirculation. 9:133–145. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Spranger S, Spaapen RM, Zha Y, Williams J,
Meng Y, Ha TT and Gajewski TF: Up-regulation of PD-L1, IDO, and
T(regs) in the melanoma tumor microenvironment is driven by CD8(+)
T cells. Sci Transl Med. 5:200ra1162013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Abiko K, Mandai M, Hamanishi J, Yoshioka
Y, Matsumura N, Baba T, Yamaguchi K, Murakami R, Yamamoto A, Kharma
B, et al: PD-L1 on tumor cells is induced in ascites and promotes
peritoneal dissemination of ovarian cancer through CTL dysfunction.
Clin Cancer Res. 19:1363–1374. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Brenner MB, McLean J, Scheft H, Riberdy J,
Ang SL, Seidman JG, Devlin P and Krangel MS: Two forms of the
T-cell receptor gamma protein found on peripheral blood cytotoxic T
lymphocytes. Nature. 325:689–694. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dunn GP, Old LJ and Schreiber RD: The
three Es of cancer immunoediting. Annu Rev Immunol. 22:329–360.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hirata S, Kubo Y, Kokubo T, Kitada M and
Nosaka T: Expression of major histocompatibility complex of
advanced non-small cell lung cancer (NSCLC). Nihon Kyobu Geka
Gakkai Zasshi. 44:138–143. 1996.(In Japanese). PubMed/NCBI
|
|
19
|
Korkolopoulou P, Kaklamanis L, Pezzella F,
Harris AL and Gatter KC: Loss of antigen-presenting molecules (MHC
class I and TAP-1) in lung cancer. Br J Cancer. 73:148–153. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ramnath N, Tan D, Li Q, Hylander BL,
Bogner P, Ryes L and Ferrone S: Is downregulation of MHC class I
antigen expression in human non-small cell lung cancer associated
with prolonged survival? Cancer Immunol Immunother. 55:891–899.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Suzuki H, Higuchi M, Hasegawa T, Yonechi
A, Ohsugi J, Yamada F, Hoshino M, Shio Y, Fujiu K and Gotoh M:
Tissue array analysis of the aberrant expression of HLA class I
molecules in human non small cell lung cancer. Gan To Kagaku Ryoho.
33:1713–1716. 2006.(In Japanese). PubMed/NCBI
|
|
22
|
Hanagiri T, Shigematsu Y, Kuroda K, Baba
T, Shiota H, Ichiki Y, Nagata Y, Yasuda M, Uramoto H, So T, et al:
Prognostic implications of human leukocyte antigen class I
expression in patients who underwent surgical resection for
non-small-cell lung cancer. J Surg Res. 181:e57–e63. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee SJ, Jang BC, Lee SW, Yang YI, Suh SI,
Park YM, Oh S, Shin JG, Yao S, Chen L, et al: Interferon regulatory
factor-1 is prerequisite to the constitutive expression and
IFN-gamma-induced upregulation of B7-H1 (CD274). FEBS Lett.
580:755–762. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mühlbauer M, Fleck M, Schütz C, Weiss T,
Froh M, Blank C, Schölmerich J and Hellerbrand C: PD-L1 is induced
in hepatocytes by viral infection and by interferon-alpha and
-gamma and mediates T cell apoptosis. J Hepatol. 45:520–528. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Abiko K, Matsumura N, Hamanishi J,
Horikawa N, Murakami R, Yamaguchi K, Yoshioka Y, Baba T, Konishi I
and Mandai M: IFN-γ from lymphocytes induces PD-L1 expression and
promotes progression of ovarian cancer. Br J Cancer. 112:1501–1509.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dunn GP, Koebel CM and Schreiber RD:
Interferons, immunity and cancer immunoediting. Nat Rev Immunol.
6:836–848. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Burnet FM: The concept of immunological
surveillance. Prog Exp Tumor Res. 13:1–27. 1970. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wei S, Shreiner AB, Takeshita N, Chen L,
Zou W and Chang AE: Tumor-induced immune suppression of in vivo
effector T-cell priming is mediated by the B7-H1/PD-1 axis and
transforming growth factor beta. Cancer Res. 68:5432–5438. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zou W and Chen L: Inhibitory B7-family
molecules in the tumour microenvironment. Nat Rev Immunol.
8:467–477. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu J, Hamrouni A, Wolowiec D, Coiteux V,
Kuliczkowski K, Hetuin D, Saudemont A and Quesnel B: Plasma cells
from multiple myeloma patients express B7-H1 (PD-L1) and increase
expression after stimulation with IFN-{gamma} and TLR ligands via a
MyD88-, TRAF6-, and MEK-dependent pathway. Blood. 110:296–304.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mansfield AS, Murphy SJ, Peikert T, Yi ES,
Vasmatzis G, Wigle DA and Aubry MC: Heterogeneity of programmed
cell death ligand 1 expression in multifocal lung cancer. Clin
Cancer Res. 22:2177–2182. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
McLaughlin J, Han G, Schalper KA,
Carvajal-Hausdorf D, Pelekanou V, Rehman J, Velcheti V, Herbst R,
LoRusso P and Rimm DL: Quantitative assessment of the heterogeneity
of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol.
2:46–54. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Akbay EA, Koyama S, Carretero J, Altabef
A, Tchaicha JH, Christensen CL, Mikse OR, Cherniack AD, Beauchamp
EM, Pugh TJ, et al: Activation of the PD-1 pathway contributes to
immune escape in EGFR-driven lung tumors. Cancer Discov.
3:1355–1363. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sumimoto H, Takano A, Teramoto K and Daigo
Y: RAS-mitogen-activated protein kinase signal is required for
enhanced PD-L1 expression in human lung cancers. PLoS One.
11:e01666262016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ota K, Azuma K, Kawahara A, Hattori S,
Iwama E, Tanizaki J, Harada T, Matsumoto K, Takayama K, Takamori S,
et al: Induction of PD-L1 expression by the EML4-ALK oncoprotein
and downstream signaling pathways in non-small cell lung cancer.
Clin Cancer Res. 21:4014–4021. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Herbst RS, Soria JC, Kowanetz M, Fine GD,
Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger
SN, et al: Predictive correlates of response to the anti-PD-L1
antibody MPDL3280A in cancer patients. Nature. 515:563–567. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Powles T, Eder JP, Fine GD, Braiteh FS,
Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, et
al: MPDL3280A (anti-PD-L1) treatment leads to clinical activity in
metastatic bladder cancer. Nature. 515:558–562. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Garber K: Predictive biomarkers for
checkpoints, first tests approved. Nat Biotechnol. 33:1217–1218.
2015. View Article : Google Scholar : PubMed/NCBI
|
